Irish Partners

NUIG - National University of Ireland Galway


NUIG is a non-profit, public body higher education establishment.  The Regenerative Medicine Institute (REMEDI, is a biomedical research centre with a central focus on the development of novel therapies for human diseases using adult stem cell and/or gene therapies. REMEDI was established at NUIG in 2004 as a Science Foundation Ireland-funded Centre for Science, Engineering and Technology with orthopaedic and cardiovascular indications as the primary disease models underpinned with strong basic research programmes on adult stem cells including bone marrow derived mesenchymal stem cells (BM-MSCs), haematopoietic stem cells, endothelial progenitors, induced pluripotent stem cells and immunology research to underpin cell therapy.  REMEDI has a fully-equipped and licensed pre-clinical facility and extensive molecular biology, cell culture and viral production (BSL2) laboratories. Core facilities specialise in human and animal MSC culture, flow cytometry and high throughput screening.  The Centre for Cell Manufacture Ireland (CCMI) is an Irish Medicines Board approved GMP facility for MSC production, based at REMEDI. The HRB Clinical Research Facility (CRF) at NUI Galway enables implementation of basic output through clinical testing, liaising with hospital partners. 



Team composition


Prof. Frank Barry, MD PhD


Professor of Cellular Therapy at NUIG, and the Scientific Director of REMEDI since 2004. He has extensive experience in MSC biology and translation. He has worked both in academia and industry in the area and directed research and development leading to the first clinical trial worldwide on BM-MSCs in an orthopaedic application while at Osiris Therapeutic Inc., Baltimore, MD, US. 



Dr Mary Murphy, PhD


Lecturer in Regenerative Medicine and a PI at REMEDI. Research interests focus on the biology, mechanism of action and the use of BM-MSC for tissue regeneration in orthopaedic applications with both academic and industrial experience including translation to human use through a first-in-man clinical trial for BM-MSC. 


Andrew Finnerty, 


General manager of CCMI, a 250m² licensed, state-of-the-art cleanroom, for manufacture of MSCs for GMP investigational patient-enrolled clinical trials, He has extensive experience in management and development of GMP processes.





Ouvre un lien externe dans une nouvelle fenêtreNUI Galway website